Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.

Madsbad S, Kilhovd B, Lager I, Mustajoki P, Dejgaard A; Scandinavian Repaglinide Group..

Diabet Med. 2001 May;18(5):395-401.

PMID:
11472451
2.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
3.

Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.

Owens DR.

Diabet Med. 1998;15 Suppl 4:S28-36. Review.

PMID:
9868989
4.

Repaglinide as monotherapy in Type 2 diabetes.

Gomis R.

Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S133-5. Review.

PMID:
10522838
5.

Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.

Culy CR, Jarvis B.

Drugs. 2001;61(11):1625-60. Review.

PMID:
11577798
6.
7.

Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.

Johansen OE, Birkeland KI.

Am J Cardiovasc Drugs. 2007;7(5):319-35. Review.

PMID:
17953471
8.

Repaglinide: a new short-acting insulinotropic agent for the treatment of type 2 diabetes.

Owens DR.

Eur J Clin Invest. 1999 Jun;29 Suppl 2:30-7. Review.

PMID:
10383608
9.

Repaglinide in combination therapy.

Moses R.

Diabetes Nutr Metab. 2002 Dec;15(6 Suppl):33-8. Review.

PMID:
12702006
10.

Pharmacology and clinical experience with repaglinide.

Massi-Benedetti M, Damsbo P.

Expert Opin Investig Drugs. 2000 Apr;9(4):885-98. Review.

PMID:
11060717
11.

Repaglinide: prandial glucose regulation in clinical practice.

Owens DR, McDougall A.

Diabetes Obes Metab. 2000 Mar;2 Suppl 1:S43-8. Review.

PMID:
11225759
12.

Repaglinide.

Balfour JA, Faulds D.

Drugs Aging. 1998 Aug;13(2):173-80. Review. Erratum in: Drugs Aging 1999 Jul;15(1):28.

PMID:
9739505
13.

Preclinical and clinical studies on safety and tolerability of repaglinide.

Schatz H.

Exp Clin Endocrinol Diabetes. 1999;107 Suppl 4:S144-8. Review.

PMID:
10522841
14.

Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?

Nattrass M, Lauritzen T.

Int J Obes Relat Metab Disord. 2000 Sep;24 Suppl 3:S21-31. Review.

PMID:
11063281
15.

Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus.

Guay DR.

Pharmacotherapy. 1998 Nov-Dec;18(6):1195-204. Review.

PMID:
9855316
16.

The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.

Owens D.

J Assoc Physicians India. 2001 Jan 25;49 Spec No:54-61. Review. No abstract available.

PMID:
11235607
17.

Meglitinide analogues for type 2 diabetes mellitus.

Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004654. Review.

PMID:
17443551
18.

Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control.

Pratley RE, Foley JE, Dunning BE.

Curr Pharm Des. 2001 Sep;7(14):1375-97. Review.

PMID:
11472274
19.

Comparison of repaglinide and metformin versus metformin alone for type 2 diabetes: a meta-analysis of randomized controlled trials.

Yin J, Deng H, Qin S, Tang W, Zeng L, Zhou B.

Diabetes Res Clin Pract. 2014 Sep;105(3):e10-5. doi: 10.1016/j.diabres.2014.06.009. Epub 2014 Jun 23. Review.

PMID:
25005849
20.

[Repaglinide (NN-623)].

Kaku K.

Nihon Rinsho. 1997 Nov;55 Suppl:180-5. Review. Japanese. No abstract available.

PMID:
9434464

Supplemental Content

Support Center